BioSpace News Archive

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020. The Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cell

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial evaluating ADX-629, a novel orally available reactive aldehyde species (RASP) inhibitor, for the treatment of adult patients hospitalized for COVID-19. “The FDA’s clearance of our Investigational New Drug application

Yulong Eco-Materials Limited (OTC PINK:YECO ) today announced that it intends to build an incubator laboratory for development of cell and extracellular vesicle (EV) based therapeutics.

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced that it has completed management changes to enhance its focus on its dermatological services and products (“DSP”) including DermSecure™ and SIAscopy™. Mike Druhan, who has championed SIAscopy™ within the Company for a number of years, has been appointed President, Dermatological Services and Products. The supporting teams in sales, training, pro

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference

Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Jack A. Khattar to its board of directors.

Rockwell Medical, Inc. announced it will host a conference call and webcast on Thursday, September 24, 2020, at 4:30 p.m. ET to discuss potential novel applications of ferric pyrophosphate citrate, the active pharmaceutical ingredient in Triferic®, for the treatment of iron deficiency anemia in patients undergoing home infusion therapy and iron deficiency in patients with acute heart failure.

OncoImmune, Inc. announced the completion of a $56 million financing in Series B equity co-led by HM Capital and a blue-chip investor.

Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces that it will participate in two virtual investor events in September 2020.

Phase III clinical trial program initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS)